Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.47 |
| ▸ | ARG2 | P78540 | 2/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25315310 | 1.00 | ARG1 (0.47) | ARG1ARG2GGT1L3MBTL1MEN1 | |
| SCHEMBL25314855 | 1.00 | ARG1 (0.47) | ARG1ARG2GGT1L3MBTL1MEN1 | |
| SCHEMBL16401328 | 0.78 | ARG1 (0.55) | ARG1ARG2GGT1ACLYTDP1 | |
| SCHEMBL19305277 | 0.78 | ARG1 (0.55) | ARG1ARG2GGT1ACLYTDP1 | |
| SCHEMBL16401653 | 0.78 | ARG1 (0.55) | ARG1ARG2GGT1ACLYTDP1 | |
| SCHEMBL18954910 | 0.78 | ARG1 (0.55) | ARG1ARG2GGT1ACLYTDP1 | |
| SCHEMBL25315695 | 0.78 | GGT1 (0.37) | ARG1ARG2GGT1L3MBTL1MEN1 | |
| SCHEMBL24633725 | 0.78 | GGT1 (0.37) | ARG1ARG2GGT1L3MBTL1MEN1 | |
| SCHEMBL25315606 | 0.78 | GGT1 (0.37) | ARG1ARG2GGT1L3MBTL1MEN1 | |
| SCHEMBL366776 | 0.77 | ARG1 (0.53) | ARG1ARG2GGT1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235301-A1 | Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235301-A1 | Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis | STING1, TK1, PCNA | ARG1 366/4885ARG2 1165/4885GGT1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.